Concert Pharmaceuticals launches Phase 3 alopecia areata trial

Concert Pharma

Concert Pharmaceuticals (NASDAQ:CNCE) initiated a Phase 3 trial to evaluate CTP-543 for the treatment of alopecia areata. 

Alopecia areata is an autoimmune disease that causes partial or complete loss of hair on the scalp and body. CTP-543 is an oral deuterium-modified ruxolitinib, which inhibits Janus kinases 1 and 2. 

The trial will enroll some 700 patients, aged 18-to-65, with more than 50% hair loss. Patients will receive either 8 mg or 12 mg of CTP-543, or placebo, twice-daily for 24 weeks. The trial’s primary endpoint is the percent of patients achieving a severity of alopecia tool, or SALT, score of greater than, or equal to 20 at week 24.

“Based on the results from our Phase 2 program, we believe CTP-543 has the potential to offer patients a best-in-class treatment for moderate to severe alopecia areata,” James Cassella, Ph.D., Concert’s chief development officer, said in a statement.

“We are fully committed to advancing CTP-543 with its breakthrough therapy designation in order to make a meaningful difference in the lives of individuals impacted by alopecia areata,” he added.

Concert expects to report topline results from the trial in 2022 and plans to launch a second Phase 3 trial in the same indication in the first half of 2021.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.